Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vera Therapeutics, Inc.

22.65
-0.6400-2.75%
Post-market: 22.650.00000.00%19:15 EDT
Volume:2.68M
Turnover:61.08M
Market Cap:1.44B
PE:-7.55
High:23.38
Open:23.19
Low:22.28
Close:23.29
Loading ...

Stock Track | Vera Therapeutics Soars 5.08% on Analyst Updates and Conference Participation

Stock Track
·
28 Feb

Vera Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
27 Feb

Wedbush Adjusts Price Target on Vera Therapeutics to $34 From $38, Maintains Neutral Rating

MT Newswires Live
·
27 Feb

Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

GlobeNewswire
·
27 Feb

Vera Therapeutics Inc : Raymond James Cuts Target Price to $73 From $76

THOMSON REUTERS
·
27 Feb

Vera Therapeutics Inc : Guggenheim Raises Target Price to $61 From $59

THOMSON REUTERS
·
27 Feb

Analysts Offer Insights on Healthcare Companies: Agilent (A) and Vera Therapeutics (VERA)

TIPRANKS
·
27 Feb

Optimistic Buy Rating for Vera Therapeutics: Strong Financials and Promising Pipeline Drive Positive Outlook

TIPRANKS
·
27 Feb

Earnings Flash (VERA) Vera Therapeutics Posts Full Year 2024 Total Operating Expenses $167.2M

MT Newswires Live
·
26 Feb

Vera Therapeutics FY 2024 GAAP EPS $(2.75) Beats $(2.83) Estimate

Benzinga
·
26 Feb

Earnings Flash (VERA) Vera Therapeutics Posts Full Year 2024 Net Loss $-2.75 a Share, vs. FactSet Est of $-2.90 Loss

MT Newswires Live
·
26 Feb

BRIEF-Vera Therapeutics FY EPS USD -2.75 Vs. IBES Estimate USD -2.84

Reuters
·
26 Feb

Vera Therapeutics FY EPS USD -2.75 VS. Ibes Estimate USD -2.84

THOMSON REUTERS
·
26 Feb

Press Release: Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Dow Jones
·
26 Feb

Vera Therapeutics selloff a buying opportunity, says Evercore ISI

TIPRANKS
·
19 Feb

Buy Rating for Vera Therapeutics: Atacicept’s Unique Potential in the IgAN Market

TIPRANKS
·
19 Feb

Vera Therapeutics selloff Friday overblown, says JPMorgan

TIPRANKS
·
18 Feb

TD Cowen Remains a Buy on Vera Therapeutics (VERA)

TIPRANKS
·
18 Feb

Buy Rating Affirmed for Vera Therapeutics Amid Promising Atacicept Prospects and Market Overreaction Concerns

TIPRANKS
·
18 Feb

Vera reaction to competitor IgAN update ‘overdone,’ says Goldman Sachs

TIPRANKS
·
15 Feb